Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction

Autor(es):Mostrar menos -

Dulce, Raul A. ; Kanashiro-Takeuchi, Rosemeire M. ; Takeuchi, Lauro M. ; Salerno, Alessandro G. ; Wanschel, Amarylis C. B. A. ; Kulandavelu, Shathiyah ; Balkan, Wayne ; Zuttion, Marilia S. S. R. ; Cai, Renzhi ; Schally, Andrew, V ; Hare, Joshua M.

• Tipo de documento: Artigo Científico
• Fonte: Cardiovascular Research; v. 118, n. 18, p. 16-pg., 2022-06-15.

Resumo

Aims To test the hypothesis that the activation of the growth hormone-releasing hormone (GHRH) receptor signalling pathway within the myocardium both prevents and reverses diastolic dysfunction and pathophysiologic features consistent with heart failure with preserved ejection fraction (HFpEF). Impaired myocardial relaxation, fibrosis, and ventricular stiffness, among other multi-organ morbidities, characterize the phenotype underlying the HFpEF syndrome. Despite the rapidly increasing prevalence of HFpEF, few effective therapies have emerged. Synthetic agonists of the GHRH receptors reduce myocardial fibrosis, cardiomyocyte hypertrophy, and improve performance in animal models of ischaemic cardiomyopathy, independently of the growth hormone axis. Methods and results CD1 mice received 4- or 8-week continuous infusion of angiotensin-II (Ang-II) to generate a phenotype with several features consistent with HFpEF. Mice were administered either vehicle or a potent synthetic agonist of GHRH, MR-356 for 4-weeks beginning concurrently or 4-weeks following the initiation of Ang-II infusion. Ang-II-treated animals exhibited diastolic dysfunction, ventricular hypertrophy, interstitial fibrosis, and normal ejection fraction. Cardiomyocytes isolated from these animals exhibited incomplete relaxation, depressed contractile responses, altered myofibrillar protein phosphorylation, and disturbed calcium handling mechanisms (ex vivo). MR-356 both prevented and reversed the development of the pathological phenotype in vivo and ex vivo. Activation of the GHRH receptors increased cAMP and cGMP in cardiomyocytes isolated from control animals but only cAMP in cardiac fibroblasts, suggesting that GHRH-A exert differential effects on cardiomyocytes and fibroblasts. Conclusion These findings indicate that the GHRH receptor signalling pathway(s) represents a new molecular target to counteract dysfunctional cardiomyocyte relaxation by targeting myofilament phosphorylation and fibrosis. Accordingly, activation of GHRH receptors with potent, synthetic GHRH agonists may provide a novel therapeutic approach to management of the myocardial alterations associated with the HFpEF syndrome. (AU)

• Processo FAPESP: 16/01044-0 - Efeitos do transplante de células-tronco mesenquimais no estresse oxidativo em camundongos GSNOR-/- e seus controles C57BL6/J.
• Beneficiário: Alessandro Gonzalez Salerno
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado